Novo Nordisk plans price cuts for some insulin

Silicon Valley Bank’s demise disrupts the disruptors in tech

Silicon Valley Bank’s collapse has rattled the technology industry that had been the bank’s backbone. It’s left shellshocked entrepreneurs thankful for the government reprieve that saved their money, while they mourned the loss of a place that served as a chummy club of innovation. Even as tech startups felt relief for the deposit guarantees that will allow them to continue to pay their workers and other bills, startup CEOs and the venture capitalists who back them worried that it may be more difficult to finance risky ideas in the future without the presence of an institution that had been a reliable partner for the past 40 years.

Class action suit filed against Silicon Valley Bank parent

A class action lawsuit is being filed against the parent company of Silicon Valley Bank, its CEO and its chief financial officer, saying that company didn’t disclose the risks that future interest rate increases would have on its business. The lawsuit is looking for unspecified damages to be awarded to those who invested in SVB Financial Group between June 16, 2021 and March 10, 2023. The lawsuit says some quarterly and annual financial reports from SVB didn’t fully account for warnings from the Federal Reserve about interest rate hikes.

Facebook parent Meta slashes another 10,000 jobs

Facebook’s parent Meta will slash another 10,000 jobs and will not fill 5,000 open positions as the social media pioneer cuts costs. The company said Tuesday it will reduce the size of its recruiting team and then make further cuts in its tech groups in late April, and then its business groups in late May. The Menlo Park, California, company has been investing billions of dollars to realign its focus on the metaverse. In February it posted lower fourth-quarter profit and revenue, hurt by a downturn in the online advertising market and competition from rivals such as TikTok.

California court rules for Uber, Lyft in ride-hailing case

A California appeals court has ruled companies like Uber and Lyft do not have to treat their drivers as employees. The ruling means app-based ride hailing and delivery companies do not have to provide certain worker protections and benefits. The state Legislature passed a law in 2019 requiring these companies to treat their drivers as employees. Companies like Uber and Lyft spent $200 million in 2020 on a campaign to convince voters to exempt them from that law. Voters agreed. In 2021 a state judge ruled the companies were not exempt from the law. Monday, a state appeals court overturned that decision.

U.S. inflation eases but stays high as Fed in tough spot

U.S. consumer price increases eased slightly from January to February but still pointed to an elevated inflation rate that is posing a challenge for the Federal Reserve at a delicate moment for the financial system. The government said Tuesday that prices increased 0.4 percent last month, just below January’s 0.5 percent rise. Yet excluding volatile food and energy costs, so-called core prices rose 0.5 percent in February, slightly above January’s 0.4 percent gain. The Fed pays particular attention to the core measure as a gauge of underlying inflation pressures.

Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.

The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30.

Novo also will drop the list price of unbranded products like Insulin Aspart to match the lower price of the branded insulins.

The price cuts go into effect Jan. 1. A vial of NovoLog and NovoLog Mix 70/30 will drop 75% to $72.34 from $289.36. FlexPen options will fall to $139.71 from more than $500.

Levemir and Novolin vials and FlexPens will drop 65% from their current list prices.

List prices are what a drugmaker initially sets for a product and what people who have no insurance or plans with high deductibles are sometimes stuck paying.

Patient advocates have long called for insulin price cuts to help uninsured people who would not be affected by price caps tied to insurance coverage. They have noted that high insulin prices force many people to ration doses, which can be dangerous for their health.

Research has shown that prices for insulin have more than tripled in the last two decades. Pressure is growing on drugmakers to help patients.

Insulin affordability in the United States depends largely on whether patients have health insurance and the details of that coverage. People with employer-sponsored coverage, for instance, may pay little out of pocket for their insulin or they might pay hundreds of dollars if they must first meet a high deductible before the coverage kicks in.

High deductibles also are common with coverage purchased through the individual insurance market.

Major insulin makers like Lilly, Novo and the French pharmaceutical company Sanofi have said they offer several assistance programs to help patients with costs. Those can include free refills for people with low incomes and cheaper versions of older insulins.

But high list prices remain a problem.

Eli Lilly and Co. CEO David Ricks noted earlier this month that discounts the drugmaker offers from its list prices often don’t reach patients.